154 related articles for article (PubMed ID: 22484722)
21. Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study.
Angarita FA; Cannell AJ; Abdul Razak AR; Dickson BC; Blackstein ME
BMC Cancer; 2016 Jan; 16():30. PubMed ID: 26786213
[TBL] [Abstract][Full Text] [Related]
22. The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
Schack LH; Mouritsen LS; Elowsson C; Krarup-Hansen A; Safwat A
Acta Oncol; 2015 Jan; 54(1):34-40. PubMed ID: 25263179
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
Demetri GD; Chawla SP; von Mehren M; Ritch P; Baker LH; Blay JY; Hande KR; Keohan ML; Samuels BL; Schuetze S; Lebedinsky C; Elsayed YA; Izquierdo MA; Gómez J; Park YC; Le Cesne A
J Clin Oncol; 2009 Sep; 27(25):4188-96. PubMed ID: 19652065
[TBL] [Abstract][Full Text] [Related]
24. Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.
Chu Q; Mita A; Forouzesh B; Tolcher AW; Schwartz G; Nieto A; Soto-Matos A; Alfaro V; Lebedinsky C; Rowinsky EK
Clin Cancer Res; 2010 May; 16(9):2656-65. PubMed ID: 20406837
[TBL] [Abstract][Full Text] [Related]
25. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.
Hensley ML; Patel SR; von Mehren M; Ganjoo K; Jones RL; Staddon A; Rushing D; Milhem M; Monk B; Wang G; McCarthy S; Knoblauch RE; Parekh TV; Maki RG; Demetri GD
Gynecol Oncol; 2017 Sep; 146(3):531-537. PubMed ID: 28651804
[TBL] [Abstract][Full Text] [Related]
27. Retrospective inter- and intra-patient evaluation of trabectedin after best supportive care for patients with advanced translocation-related sarcoma after failure of standard chemotherapy.
Araki N; Takahashi S; Sugiura H; Ueda T; Yonemoto T; Takahashi M; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Kawai A
Eur J Cancer; 2016 Mar; 56():122-130. PubMed ID: 26845175
[TBL] [Abstract][Full Text] [Related]
28. Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials.
del Campo JM; Sessa C; Krasner CN; Vermorken JB; Colombo N; Kaye S; Gore M; Zintl P; Gómez J; Parekh T; Park YC; McMeekin S
Med Oncol; 2013 Mar; 30(1):435. PubMed ID: 23397080
[TBL] [Abstract][Full Text] [Related]
29. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study.
Kawai A; Araki N; Sugiura H; Ueda T; Yonemoto T; Takahashi M; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Tanase T; Hasegawa T; Takahashi S
Lancet Oncol; 2015 Apr; 16(4):406-16. PubMed ID: 25795406
[TBL] [Abstract][Full Text] [Related]
30. Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.
Awada A; Cortés J; Martín M; Aftimos P; Oliveira M; López-Tarruella S; Espie M; Lardelli P; Extremera S; Fernández-García EM; Delaloge S
Clin Breast Cancer; 2016 Oct; 16(5):364-371. PubMed ID: 27266804
[TBL] [Abstract][Full Text] [Related]
31. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.
Baruchel S; Pappo A; Krailo M; Baker KS; Wu B; Villaluna D; Lee-Scott M; Adamson PC; Blaney SM
Eur J Cancer; 2012 Mar; 48(4):579-85. PubMed ID: 22088484
[TBL] [Abstract][Full Text] [Related]
32. Trabectedin for advanced soft tissue sarcomas: a single institution experience.
Gounaris I; Hatcher HM; Davidson D; Sherbourne K; Alam S; Zaki KA; Horan G; Earl HM
Future Oncol; 2014 Aug; 10(11):1843-51. PubMed ID: 24450573
[TBL] [Abstract][Full Text] [Related]
33. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.
Le Cesne A; Reichardt P
Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310
[TBL] [Abstract][Full Text] [Related]
34. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.
Del Campo JM; Roszak A; Bidzinski M; Ciuleanu TE; Hogberg T; Wojtukiewicz MZ; Poveda A; Boman K; Westermann AM; Lebedinsky C;
Ann Oncol; 2009 Nov; 20(11):1794-802. PubMed ID: 19556318
[TBL] [Abstract][Full Text] [Related]
35. Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.
Lorusso D; Scambia G; Pignata S; Sorio R; Amadio G; Lepori S; Mosconi A; Pisano C; Mangili G; Maltese G; Sabbatini R; Artioli G; Gamucci T; Di Napoli M; Capoluongo E; Ludovini V; Raspagliesi F; Ferrandina G
Ann Oncol; 2016 Mar; 27(3):487-93. PubMed ID: 26681678
[TBL] [Abstract][Full Text] [Related]
36. Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project.
Di Napoli M; Della Pepa C; Arenare L; Scambia G; Lorusso D; Raspagliesi F; Ferrandina G; Salutari V; Sorio R; Mosconi AM; Mangili G; Borgato L; Lepori S; Salvino A; Pignata S; Cecere SC
Support Care Cancer; 2017 Jun; 25(6):1743-1748. PubMed ID: 28101677
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study.
Kobayashi H; Iwata S; Wakamatsu T; Hayakawa K; Yonemoto T; Wasa J; Oka H; Ueda T; Tanaka S
Cancer; 2020 Mar; 126(6):1253-1263. PubMed ID: 31825533
[TBL] [Abstract][Full Text] [Related]
38. 13 years of trabectedin, 5 years of Yondelis®: what have we learnt?
Le Cesne A
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):11-9. PubMed ID: 23638726
[TBL] [Abstract][Full Text] [Related]
39. A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors.
Chuk MK; Aikin A; Whitcomb T; Widemann BC; Zannikos P; Bayever E; Balis FM; Fox E
Pediatr Blood Cancer; 2012 Nov; 59(5):865-9. PubMed ID: 22847981
[TBL] [Abstract][Full Text] [Related]
40. The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer.
Prado CM; Baracos VE; Xiao J; Birdsell L; Stuyckens K; Park YC; Parekh T; Sawyer MB
Appl Physiol Nutr Metab; 2014 Jun; 39(6):693-8. PubMed ID: 24869973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]